HIV Injections Outperform Daily Tablets in Adolescent Trial
Adolescents living with HIV may achieve better control of the virus with long-acting injections given every eight weeks than with the daily tablets that have long been standard care, according to results from a clinical trial led by researchers at University College London. The findings, published in The Lancet, add a significant new dimension to global efforts to improve HIV treatment for an age group that has historically lagged behind adults in treatment outcomes.
The trial, known as LATA, short for Long-Acting Treatment in Adolescents, was carried out in Kenya, South Africa, Uganda and Zimbabwe. It compared a daily oral antiretroviral regimen with an injectable treatment combining cabotegravir and rilpivirine. The research team reported that the injections were more effective at keeping the virus suppressed than the tablets were, a result that stands out because earlier trials in adults had shown only that injectables were no less effective than daily pills.
Why Daily Pills Are a Struggle for Young People
Daily antiretroviral therapy has transformed HIV from a fatal illness into a manageable chronic condition, allowing people to live long and healthy lives and sharply reducing the risk that the virus will be passed to others. Yet adherence remains difficult for many patients, and adolescents face a distinct set of pressures.
- Stigma: taking medication every day can mark a young person as different in settings where HIV is still heavily stigmatized.
- Bullying: peers may single out classmates who are known to take regular medication, making treatment a source of social harm rather than support.
- Privacy: storing and taking pills at school, at home or in shared housing makes it hard to keep a diagnosis confidential.
- Routine disruption: the demands of daily dosing can clash with unpredictable schedules, travel and the ordinary chaos of teenage life.
Sarah Pett of the UCL Innovative Clinical Trials Unit, the trial's chief investigator, observed that HIV-positive adolescents as a group have historically fared worse on antiretrovirals than adults. Bullying and stigma associated with daily pill-taking are part of the problem, she said, while long-acting injectables taken every two months could help young people lead more normal lives. She also noted that the benefits seen in adolescents appear stronger than those observed in adult studies.
Inside the LATA Trial
Who Took Part
The study enrolled 476 adolescents between the ages of 12 and 19 at five clinics across the four participating countries. Volunteers were randomly assigned either to continue standard daily tablet treatment or to switch to the long-acting injectable. Almost all of the participants had been living with HIV since birth, reflecting the reality that many adolescents acquired the virus through mother-to-child transmission years earlier. To qualify for the trial, they had to have been on tablet treatment for more than a year, to have fully suppressed and undetectable virus, and to have no history of treatment failure.
The Treatment Compared
One arm of the study kept participants on the daily oral regimen that is considered standard care. The other arm received cabotegravir and rilpivirine, a relatively new injectable combination for HIV treatment, administered every eight weeks. Because the participants were already stable on tablets and had undetectable viral loads, the trial was designed to test whether the injectable approach could match or surpass the outcomes achieved with daily pills in a group known to struggle with adherence.
What the Team Found
The researchers reported that the injectable regimen kept the virus suppressed more effectively than daily tablets. That outcome was more striking than the results of previous adult trials, which had established only that long-acting injections were not inferior to oral therapy. In other words, the adolescent data point to an advantage, not merely an equivalence, for the two-monthly shots.
What the Results Mean for HIV Care
About 1.6 million adolescents between the ages of 10 and 19 are living with HIV worldwide. Although the virus remains incurable, antiretrovirals allow people to live long, healthy lives and greatly reduce the risk of onward transmission. If injections can help adolescents maintain viral suppression more reliably, the implications reach beyond any single patient.
- Better adherence: an injection every eight weeks removes the daily reminder and the daily decision to take a pill.
- Less stigma: treatment becomes a private clinical appointment rather than a visible part of everyday life.
- Sustained suppression: keeping the virus undetectable protects the individual's health and lowers the chance of transmission to partners.
- Life stage fit: a regimen that does not intrude on school, friendships and growing independence may suit adolescents better than one that does.
Pett argued that the results support making injectables more widely available to groups, such as adolescents, who may not do as well on daily tablets. The findings therefore feed directly into a broader conversation about how HIV services should be tailored rather than delivered in a single standardized form.
The Access Gap
The most immediate obstacle is availability. Nine out of ten adolescents with HIV live in Africa, yet the injectable treatment is currently not accessible to them, according to the researchers. The LATA trial demonstrated that the approach can be delivered in clinics in Kenya, South Africa, Uganda and Zimbabwe, but running a study is not the same as providing routine care at scale. Making the regimen widely available would require decisions about pricing, procurement, supply chains and clinic capacity, as well as training for health workers who would administer the injections.
Open Questions and Next Steps
The trial answers an important question about efficacy, but it leaves others open. Researchers will want to understand how acceptable the injections prove over longer periods, whether adolescents continue to attend appointments for dosing, and how the approach performs outside the carefully controlled conditions of a clinical trial. Participants who had already experienced treatment failure were excluded, so the results do not yet speak to that group. Cost and cold-chain requirements may also shape how quickly the regimen can spread across the regions where the need is greatest.
Even so, the direction of travel is clear. A treatment that fits the lives of young people more naturally than a daily pill could change both clinical outcomes and the experience of growing up with HIV. The LATA team's message is that this option should no longer be limited to adults in wealthy settings.
The Bottom Line
In a trial spanning four African countries, long-acting HIV injections given every eight weeks outperformed daily tablets at keeping the virus suppressed in adolescents aged 12 to 19. The result is stronger than what adult studies have shown, and it arrives in a population that has long had worse outcomes on oral therapy. With 1.6 million adolescents living with HIV and nine in ten of them in Africa, the case for widening access to injectable treatment is now backed by evidence as well as by the everyday realities of teenage life.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
